Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Debt / NOTE 2.500% 9/1
-
Market price (% of par)
-
85.06%
-
Total 13F principal
-
$202,164,345
-
Principal change
-
+$1,371,331
-
Total reported market value
-
$171,528,963
-
Number of holders
-
32
-
Value change
-
-$1,715,628
-
Number of buys
-
14
-
Number of sells
-
8
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 as of Q2 2021
As of 30 Jun 2021,
TRAVERE THERAPEUTICS INC - NOTE 2.500% 9/1 was held by
32 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$202,164,345
in principal (par value) of the bond.
The largest 10 bondholders included
D. E. Shaw & Co., Inc., DeepCurrents Investment Group LLC, Opti Capital Management, LP, UBS OCONNOR LLC, ADVENT CAPITAL MANAGEMENT /DE/, SILVERBACK ASSET MANAGEMENT LLC, CAPSTONE INVESTMENT ADVISORS, LLC, Verition Fund Management LLC, Affinity Asset Advisors, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
32
institutional bondholders reporting positions
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.